BioFreedom French Registry

NCT ID: NCT03745066

Last Updated: 2021-04-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-04-04

Study Completion Date

2022-04-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, observational multi-center registry to be conducted at up to 25 French interventional cardiology centers. Patients will be eligible once they have received at least one BioFreedomTM DCS as per standard clinical practice and will be followed for up to 2 years post PCI for data collection.

The purpose of the registry is to explore the safety and effectiveness of the BioFreedomTM DCS in standard clinical practice in France and to serve as part of Post Market Surveillance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective, observational multi-center registry to be conducted at up to 25 French interventional cardiology centers. Patients will be eligible once they have received at least one BioFreedomTM DCS as per standard clinical practice and will be followed for up to 2 years post PCI for data collection.

The registry will be purely observational and will not interfere with physician's decisions relating to stent selection or indication for treatment.

The purpose of the registry is to explore the safety and effectiveness of the BioFreedomTM DCS in standard clinical practice in France and to serve as part of Post Market Surveillance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients treated with one or more BioFreedom™ DCS .Patients who agree to comply with the follow up requirements. .Patients with a life expectancy of \> 1 year at time of consent. .Patients eligible to receive dual anti platelet therapy (DAPT).
* Patients who have signed an Informed Consent

Exclusion Criteria

* Patients unable or unwilling to give documented informed consent
* Patients taking part in another interventional trial which has not completed follow-up for the primary endpoint .Patient has received an additional stent different from a BioFreedom™ DCS stent during the index procedure.
* Pregnant or breastfeeding women
* Planned surgery within 6 months of percutaneous coronary intervention (PCI) unless dual antiplatelet therapy is maintained throughout the peri surgical period for non HBR patients
* Planned surgery within 1 month of percutaneous coronary intervention (PCI) unless dual antiplatelet therapy is maintained throughout the peri surgical period for HBR patients
* Patients under judicial protection, tutorship or curatorship
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

European Cardiovascular Research Center

NETWORK

Sponsor Role collaborator

Biosensors Europe SA

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janusz Lipiecki, MD

Role: PRINCIPAL_INVESTIGATOR

Clinique des Dômes

Philippe Garot, MD

Role: PRINCIPAL_INVESTIGATOR

ICPS, Massy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinique Des Dômes

Clermont-Ferrand, Cedex 2, France

Site Status

at Hôpital Privé Claude Galien ICPS

Quincy-sous-Sénart, Essonne, France

Site Status

Clinique de Fontaine

Fontaine-lès-Dijon, , France

Site Status

Centre Hospitalier General

Haguenau, , France

Site Status

Clinique Saint Martin

Pessac, , France

Site Status

CHU Toulouse Rangeuil

Toulouse, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18-EU-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

e-BioMatrix 6 Month DAPT France
NCT03461484 COMPLETED
VerifyNow French Registry
NCT00753753 COMPLETED
e-BioMatrix PostMarket Registry
NCT01289002 COMPLETED
VitaFlow LIBERTY Europe
NCT06535659 RECRUITING
French Registry Conducted on E-vita OPEN NEO
NCT05721001 ACTIVE_NOT_RECRUITING
ULTRA LONG: BioFreedom Ultra
NCT05643430 ACTIVE_NOT_RECRUITING NA